IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2833
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$9.9B
Neil Kumar
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$BBIO BridgeBio Pharma, Inc. | 45 | 36 | 42 | 73 | - | - | 51.3% | -70.4% | 91.8% | -1837.5% | -1619.3% | 5467.3% | 0.0% | - | $9.9B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
BridgeBio Pharma, Inc. (BBIO) receives a "Reduce" rating with a composite score of 44.8/100. It ranks #2833 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
No analyst ratings for BBIO.
View All RatingsVerified SEC Filings Aggregate
Access the primary source of truth. Direct unfiltered access to 10-K, 10-Q and 8-K filings for BBIO.
Open Regulatory DossierFigures adjusted for stock splits and restatements where applicable.
TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Neil Kumar
Chief Executive Officer
Labor Force
400
36
17
62
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for BBIO
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 36 | 13 | +23ALPHA |
| MOMENTUM | 73 | 75 | -2NEUTRAL |
| VALUATION | 42 | 21 | +21ALPHA |
| INVESTMENT | 17 | 1 | +16ALPHA |
| STABILITY | 62 | 53 | +9ALPHA |
| SHORT INT | 22 | 7 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -9.5% vs WACC 8.8% (spread -18.3%)
GM 92% vs sector 43%, OM -1837% vs sector 1%
Capital turnover 0.10x, R&D intensity 96.4%
Rev growth 5467%, 7yr history
Interest coverage -3.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
BridgeBio Pharma, Inc. receives a Reduce rating from our analysis, with a composite score of 44.8/100 and 2 out of 5 stars, ranking #2833 out of 7,333 stocks. BBIO's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
BBIO's quality score of 36/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 51.3% (sector avg: -2.5%), gross margins of 91.8% (sector avg: 42.5%), net margins of -1619.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 42/100, BBIO appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
BridgeBio Pharma, Inc.'s investment score of 17/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 5467.3% vs. a sector average of 5.9% and a return on assets of -70.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
BBIO shows strong momentum characteristics with a score of 73/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 5467.3% year-over-year, while a beta of 1.04 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 62/100, BBIO exhibits average financial resilience. Key stability metrics include a beta of 1.04. While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
BridgeBio Pharma, Inc.'s short interest score of 22/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. At $9.9B (mid-cap), BBIO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
BridgeBio Pharma, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2833 of 7,333 overall (61st percentile). Key comparisons include ROE of 51.3% exceeding the -2.5% sector median and operating margins of -1837.5% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BBIO currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (17) would have the largest impact on the composite score.
ROE 2169% BELOW SECTOR MEDIAN
Gross Margin 116% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 142540% BELOW SECTOR MEDIAN
Relative to Manufacturing Median (N=1906)
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Neutral
Bullish Accumulation
Low
Institutional cap table data requires verified 13F filing feeds.
Access SEC 13F Dossier →Insider transaction data currently awaiting regulatory verification.
Access SEC Form 4 Dossier →Smart Money conviction levels above 70 indicate significant institutional accumulation.
Data aggregates 13F and Form 4 filings with a 24-hour verification delay.
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate BridgeBio Pharma, Inc. (BBIO) as a Reduce with a composite score of 44.8/100 at a current price of $68.36. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (73th percentile) and stability (62th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (17th percentile) and quality (36th percentile) tempers our overall conviction. We assign a Narrow Moat rating (43/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
BridgeBio Pharma, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 44.8/100 places it at rank #2833 in our full 7,333-stock universe. At $9.9B in market capitalization, BridgeBio Pharma, Inc. is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 5467% and momentum in the 73th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 17th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 92% (+49.3pp vs sector) narrow to operating margins of -1837% (-1838.8pp vs sector) and net margins of -1619.3%, yielding a gross-to-net conversion rate of -1764%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
We assign BridgeBio Pharma, Inc. a Narrow Moat rating with a composite moat score of 43/100. The ROIC-WACC spread of -18.3% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that BridgeBio Pharma, Inc. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being reinvestment efficiency at 14/20.
The strongest moat sources are reinvestment efficiency (14/20) and margin superiority (12.9/20). Capital turnover 0.10x, R&D intensity 96.4%. GM 92% vs sector 43%, OM -1837% vs sector 1%. These pillars form the core of BridgeBio Pharma, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (1.3/20) and economic value creation (4/20). Interest coverage -3.0x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect BridgeBio Pharma, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
At a current price of $68.36, BridgeBio Pharma, Inc. is trading near fair value based on current fundamentals. Our value factor score of 42/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/S of 37.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Key profit drivers include gross margins of 92% providing a solid profitability foundation, robust top-line growth of 5467% expanding the revenue base, returns on equity of 51.3% driving shareholder value creation. The margin cascade from 92% gross to -1837% operating to -1619.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 36th percentile.
The margin profile shows gross margins of 92%, operating margins of -1837%, net margins of -1619.3%. Return metrics include ROE of 51.3% and ROA of -70.4%. Relative to the Manufacturing sector, gross margins are 49.3 percentage points above the sector median of 43%, and ROE of 51.3% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of 5467%. Overall balance sheet health is adequate for the current business environment.
Gross margins of 92% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 51.3% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 5467% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Positive momentum (73th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 44.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -1619.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Medium uncertainty rating to BridgeBio Pharma, Inc.. The stock presents a balanced risk profile: current negative profitability (net margin -1619.3%). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -1619.3%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 62th percentile and quality factor at the 36th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 92% provide a buffer against cost pressures; above-average stability (62th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate BridgeBio Pharma, Inc.'s capital allocation as Poor. Key concerns include negative profitability, weak asset returns (ROA -70.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — BridgeBio Pharma, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, BridgeBio Pharma, Inc. receives a Reduce rating with a composite score of 44.8/100 (rank #2833 of 7,333). Our quantitative framework assigns a Narrow Moat (43/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 46/100.
Our analysis does not support a constructive view on BridgeBio Pharma, Inc. at this time. The combination of the current quantitative profile, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Above 50MA
37.18%
Net New Highs
+51081
BridgeBio Pharma's (BBIO) stock surged 6.8% likely due to promising late-stage clinical trial data for its investigational drug BBP-418 and the strong adoption of its marketed therapy, Attruby. The company also reported a solid cash position for 2025, ensuring funding for future clinical activities. Analysts expect significant revenue growth and a reduced quarterly loss for BBIO, with earnings estimates showing a positive revision trend.
Oppenheimer has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $83.00, reiterating an "outperform" rating, following encouraging Phase 3 trial results for oral infigratinib. This aligns with other analyst upgrades and contributes to a "Moderate Buy" consensus. Despite positive clinical news, the article notes recent insider selling and potential negative earnings in the near term.
BridgeBio Pharma Inc. (BBIO) stock reached an all-time high of $84.51, marking a significant 132.35% increase over the past year. This surge is supported by a market capitalization exceeding $14 billion, strong revenue growth of 62.46%, and a "Strong Buy" analyst consensus, despite some analyses suggesting it may be trading above its Fair Value. Recent positive Phase 3 trial results for its achondroplasia treatment, infigratinib, and a $550 million convertible senior notes offering further underscore investor confidence and strategic advancement.
BridgeBio Pharma (NASDAQ:BBIO) shares gapped up premarket, opening at $70.07. The company has a current market cap of $13.39 billion and is largely rated as a "Moderate Buy" by analysts, with an average price target of $79.05, following several recent target increases. Despite insider selling activity, institutional investors hold a significant majority of the company's stock.
Y Intercept Hong Kong Ltd significantly reduced its stake in BridgeBio Pharma (NASDAQ:BBIO) by 93.4% in the third quarter, now holding $724,000 worth of shares. Despite this, analysts generally maintain a "Moderate Buy" rating with an average price target of $79.05, and some have recently raised their targets. Insider selling has also occurred, with executives disposing of shares totaling over $26 million, though insiders still own 18.20% of the company.